Revenues (Tables)

6 Months Ended

Jun. 30, 2026

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue by Product and by Geographic Area

Revenues were as follows (in millions):


						Three months ended June 30,
						2026																		2025
						U.S.						ROW						Total						U.S.						ROW						Total
Repatha						$	510					$	443					$	953					$	361					$	335					$	696
Prolia						478						281						759						745						377						1,122
EVENITY						550						164						714						395						123						518
TEPEZZA						520						56						576						466						39						505
Otezla						431						60						491						512						106						618
ENBREL						574						6						580						597						7						604
BLINCYTO						285						187						472						270						114						384
Nplate						275						155						430						228						141						369
TEZSPIRE(1)						486						—						486						342						—						342
XGEVA						187						165						352						347						185						532
Aranesp						94						258						352						107						252						359
KRYSTEXXA						399						1						400						349						—						349
KYPROLIS						201						113						314						232						146						378
Vectibix						167						171						338						144						161						305
UPLIZNA						317						18						335						132						44						176
IMDELLTRA/IMDYLLTRA						233						55						288						107						27						134
Other products(2)						1,283						414						1,697						990						390						1,380
Total product sales(3)						$	6,990					$	2,547					9,537						$	6,324					$	2,447					8,771
Other revenues																		517																		408
Total revenues																		$	10,054																	$	9,179
























						Six months ended June 30,
						2026																		2025
						U.S.						ROW						Total						U.S.						ROW						Total
Repatha						$	975					$	854					$	1,829					$	704					$	648					$	1,352
Prolia						939						547						1,486						1,465						756						2,221
EVENITY						981						295						1,276						715						245						960
TEPEZZA						944						122						1,066						831						55						886
Otezla						783						139						922						855						200						1,055
ENBREL						888						12						900						1,101						13						1,114
BLINCYTO						506						381						887						543						211						754
Nplate						558						284						842						429						253						682
TEZSPIRE(1)						829						—						829						627						—						627
XGEVA						415						348						763						707						391						1,098
Aranesp						171						492						663						198						501						699
KRYSTEXXA						654						1						655						585						—						585
KYPROLIS						419						225						644						448						254						702
Vectibix						303						322						625						279						293						572
UPLIZNA						563						34						597						214						53						267
IMDELLTRA/IMDYLLTRA						421						125						546						186						29						215
Other products(2)						2,414						811						3,225						2,099						756						2,855
Total product sales(3)						$	12,763					$	4,992					$	17,755					$	11,986					$	4,658					$	16,644
Other revenues																		917																		684
Total revenues																		$	18,672																	$	17,328

_______

(1) TEZSPIRE is marketed by our collaborator AstraZeneca outside the United States.

(2) Consists of product sales of our non-principal products.

(3) Hedging gains and losses, which are included in product sales, were not material for the three and six months ended June 30, 2026 and 2025.